Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy‐proven histological damage†

• DOI: 10.1002/hep.23424
• Publication Date: 2009-11-09T14:32:41Z
• Authors: I‐Chin Wu; Ching‐Lung Lai; Steven‐Huy Bui Han; Kwang‐Hyup Han; Stuart C. Gordon; You‐Chen Chao; Chee‐Kiat Tan; William Sievert; Tawesak Tanwandee; Dong Xu; Boon‐Leong Neo; Ting‐Tsung Chang
• Keywords: Entecavir; Alanine aminotransferase

Current guidelines for management of chronic hepatitis B recommend treatment patients presenting with elevated virus (HBV) DNA and alanine aminotransferase (ALT) >2 × upper limit normal (ULN) or histological evidence liver disease. Retrospective analyses have demonstrated that significant hepatic necroinflammation fibrosis were present in a substantial proportion ALT 1 to 2 ULN. To assess therapeutic efficacy this clinical setting, we retrospectively examined endpoints among the subset nucleoside-naïve (CHB) treated phase 3 trials entecavir who had both screening baseline serum 1.3 A total 1347 randomized lamivudine. Three hundred thirty-six patients, constituting 25% study population, Clinically (Knodell score ≥7) was observed 60% 72% e antigen (HBeAg)-positive HBeAg-negative respectively, whereas marked (Ishak ≥4) 8% 15% HBeAg-positive respectively. Among entecavir-treated proportions achieving improvement, HBV <300 copies/mL, normalization similar between mildly those However, lower response rates less than 300 normalization, HBeAg seroconversion greater Conclusion: This retrospective analysis CHB responded similarly irrespective level. well did (HEPATOLOGY 2010.)